Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted to the known alkylator melphalan leading...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Schepsky, Alexander, Traustadottir, Gunnhildur Asta, Joelsson, Jon Petur, Ingthorsson, Sævar, Kricker, Jennifer, Bergthorsson, Jon Thor, Asbjarnarson, Arni, Gudjonsson, Thorkell, Nupponen, Nina, Slipicevic, Ana, Lehmann, Fredrik, Gudjonsson, Thorarinn
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Cancer Biology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7520280/
https://ncbi.nlm.nih.gov/pubmed/32717133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3300
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi